Trump to impose 100% tariff on China starting November 1
Investing.com - Kairos Pharma (NYSE:KAPA) stock gained after H.C. Wainwright reiterated its Buy rating and $12.00 price target on the company following positive interim data from a Phase 2 study. The price target represents significant upside potential for the micro-cap company, currently valued at $25.31 million, despite its recent 22.78% decline over the past week.
The company announced positive interim safety and efficacy results from its ongoing randomized Phase 2 study of ENV-105, a first-in-class anti-CD105 antibody, in combination with apalutamide for patients with metastatic castration-resistant prostate cancer who have failed at least one prior line of androgen receptor hormone therapy. According to InvestingPro data, KAPA maintains a strong liquidity position with a current ratio of 7.16, providing runway for its clinical development programs.
Among eight evaluable patients, median progression-free survival exceeded 13 months, significantly above benchmarks from prior standard-of-care therapies, with five patients remaining on treatment without progression. The benchmark for response was considered to be progression-free survival beyond 4 months. Want deeper insights? InvestingPro subscribers have access to 8 additional key tips about KAPA’s financial health and market position.
The combination treatment also led to a reduction in PSA from baseline at the 16-week evaluation mark, providing further evidence of clinical activity. This predetermined interim analysis builds upon the same 10 patients from the safety-arm of the trial, which previously reported no dose-limiting toxicities or unexpected adverse events.
H.C. Wainwright noted that while the sample size is small and the data is early, the firm is encouraged by the preliminary progression-free survival and safety benefits, particularly when compared to past landmark studies in the indication.
In other recent news, Kairos Pharma has reported promising interim data from its Phase 2 clinical trial of ENV105 (carotuximab) in combination with apalutamide for patients with metastatic castration-resistant prostate cancer. The trial showed a median progression-free survival of more than 13 months among eight evaluable patients, with five continuing treatment without disease progression. Additionally, seven out of nine patients demonstrated decreased prostate-specific antigen levels from baseline. The company also announced positive safety results from the same trial, noting that ENV105 was well tolerated with no dose-limiting toxicities or unexpected adverse events observed. Furthermore, Kairos Pharma will present initial Phase 1 data for its cancer therapeutic ENV105 at the upcoming World Lung Cancer Conference in Barcelona. The presentation will focus on the combination of ENV105 with osimertinib for advanced, EFGR-mutated non-small cell lung cancer patients. These developments highlight Kairos Pharma’s ongoing efforts in advancing its cancer therapies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.